Valirx (VAL)

 

VAL Share PerformanceMore

52 week high11.4900 04/10/16
52 week low1.0000 19/09/17
52 week change -5.4250 (-83.46%)
4 week volume38,168,110 24/08/17

Media for (VAL)

Presenter: Dr George Morris
07/09/2017
Presenter: Suzanne Dilly
15/06/2017

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Issue of Equity

RNS Number: 0927R ValiRx PLC 19 September 2017 19 September 2017 ValiRx Plc ("ValiRx" or the "Company") Issue of Equity ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, is pleased to announce a placing to raise 0.5 million. The Company has raised 0.5 million of gross proceeds through the issue of 50,000,000 new ordinary shares at a price of 1 pe...

Hardman Research: GeneICE and VAL101 progress

RNS Number: 6222Q ValiRx PLC 13 September 2017 Hardman Research: GeneICE and VAL101 progress GeneICE and VAL101 progress: ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company's two leading assets are in clinical trials: ...

ValiRx reports good progress in developing GeneICE technology platform

ValiRx reported a period of continued good progress in the development of its GeneICE technology platform, in which "re...

GeneICE & VAL101 Update

RNS Number: 0317Q ValiRx PLC 07 September 2017 ValiRx Plc ("ValiRx" or the "Company") GENEICE & VAL101 UPDATE "Successful optimisation of VAL101 for improved commercial production" "Acceleration of pre-clinical studies" London, UK ., 07 September 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to r eport on a p...

ValiRx - GeneICE & VAL101 Update

Convertible Loan Facility

RNS Number: 7140N ValiRx PLC 11 August 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Convertible Loan Facility London, UK., 11 August 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has drawn down US$400,000 of the third tranche of its Convertible Loan Facility (announced on 02 September 2016) wi...

Conversion of Loan Note

RNS Number: 8102M ValiRx PLC 02 August 2017 ValiRx Plc ("ValiRx" or the "Company") Loan Note Conversion and Issue of Equity London, UK ., 2 August 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation...

ValiRx signs first product licensing agreement

ValiRx (VAL), a clinical stage biotechnology company, has signed a licensing agreement with Mystic Pharmaceuticals in B...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Equity Research (VAL)

hardman & co
ValiRx plc
14/09/2017
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading...
hardman & co
ValiRx plc
31/05/2017
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading...
edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

  • Re: The 2.5p placing yesterday.

    RNS placing @ 1p Price down 22% to match it. Beaufort again 500000 raised ...( can not of helped Beaufort are banned from accepting new moneys )
    19-Sep-2017
    Ripley94
  • Why is there not a use as toilet paper rec?

    Maybe the directors of this company should consider homeopathic remedies as the value of shareholders stakes has been diluted beyond invisibility! The efficacy argument for the ...
    19-Sep-2017
    Tripod99
  • Con artist

    That's all George Morris was...this company never had a hope of succeeding because of lack of funds. We haven't heard a word from anyone as to how the patients are doing and ...
    19-Sep-2017
    southernstar

Users' HoldingsMore

Users who hold Valirx also hold..
RANGE RES.17%
ROCKHOPPER17%
SOUND ENERGY16%
LLOYDS GRP.16%
SAREUM15%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL